 |
|
|
Glaxo Wellcome And BioFocus Enter Compound Library Synthesis Collaboration
Sittingbourne, UK, 7 October 1999 - BioFocus plc announced today
that it has been awarded a contract by Glaxo Wellcome S.p.A, Italy, to
produce high quality, exclusive compounds for its drug discovery programmes.
No financial details have been disclosed.
Dr David Stone, BioFocus? CEO said, "We are obviously very pleased to
be working with such a major player as Glaxo Wellcome and look forward
very much to further collaboration in the future. BioFocus has been very
successful this year in securing similar collaborations and this complements
well the expansion of our compound design and synthesis capabilities and
the recent introduction of our SoftFocusTM
range of screening libraries."
Since the launch of BioFocus just over two years ago, the UK based company
has successfully entered into collaborations with a wide range of companies
in Europe, the USA and Japan. The company provides integrated chemistry
services for the pharmaceutical and biotechnology industry, specialising
in high quality lead generation and lead optimisation solutions for drug
discovery. It has expertise in medicinal, combinatorial and computational
chemistry and broad-based industry experience covering a wide range of
therapeutic areas.
In North America :
Marcy Saack or Jeff Hoyak with MCS, at +1 908 273-9626
Outside North America :
Emma Ongley with Grayling, at + 44 171 255 1100.
At BioFocus :
Dr David Stone, Chief Executive Officer or
Mr Alan Clabon, Marketing and Customer Relations Director
Tel +44 (0)1795 412300 Fax +44 (0)1795 471123
|
|
|
